Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glen Laird

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)Lei Zhang, David Lebwohl, Eric Masson, et al.
Journal of Biopharmaceutical Statistics|October 12, 2017
Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identificationYang Zhao, Wei Zheng, Daisy Y Zhuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat)Lei Zhang, David Lebwohl, Eric Masson, et al.
Journal of Biopharmaceutical Statistics|October 12, 2017
Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identificationYang Zhao, Wei Zheng, Daisy Y Zhuo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignanciesFrancis Giles, Thomas Fischer, Jorge Cortes, et al.
Pageof 2